Day: December 14, 2020

Un total de 510 patients recrutésAtteinte du nombre d’événements requis pour déclencher l’analyse intermédiaire d’efficacitéAnalyse intermédiaire d’efficacité et analyse finale respectivement attendues au 1ertrimestre 2021 et au 4èmetrimestre 2021LYON, France, 14 déc. 2020 (GLOBE NEWSWIRE) — ERYTECH Pharma (Euronext Paris et Nasdaq : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui la finalisation du recrutement dans l’étude de phase 3 TRYbeCA-1 dans le traitement en seconde ligne du cancer du pancréas.TRYbeCA-1, l’essai clinique pivot de phase 3 évaluant le produit candidat phare d’ERYTECH, eryaspase, dans le traitement de seconde ligne du cancer du pancréas métastatique, a terminé...

PARIS, 14 déc. 2020 (GLOBE NEWSWIRE) — Cellectis S.A. (Nasdaq: CLLS – Euronext Growth: ALCLS), société biopharmaceutique de stade clinique spécialisée dans le développement d’immunothérapies fondées sur les cellules CAR-T allogéniques ingénierées (UCART), annonce le lancement, sous réserve des conditions de marché, d’une offre au public aux Etats-Unis et d’une offre adressée uniquement à des investisseurs qualifiés dans certains autres pays, portant sur un montant total de 100 millions de dollars d’American Depositary Shares (ADS), chacune représentant une action ordinaire Cellectis. Dans le contexte de cette offre, Cellectis envisage de consentir aux banques garantes une option de sur-allocation leur permettant de souscrire, pendant 30 jours, un nombre d’ADS additionnels représentant au maximum 15% du nombre d’ADS initialement...

NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) — Cellectis S.A. (Paris:ALCLS) (NASDAQ:CLLS) (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells, today announced the launch, subject to market conditions, of an underwritten public offering of $100 million of its American Depositary Shares (“ADS”), each representing one ordinary share of Cellectis. In connection with the offering, Cellectis expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the aggregate offering size on the same terms and conditions.Citigroup, Jefferies and Barclays are acting as joint book-running managers for the offering. In addition, William Blair is acting as lead manager and Kempen & Co is acting as co-manager...

WASHINGTON, Dec. 14, 2020 (GLOBE NEWSWIRE) — WashREIT (NYSE:WRE), a leading owner of multifamily and commercial properties in the Washington Metro area, will release fourth quarter earnings results after market close on Thursday, February 11, 2021.The conference call will be held on Friday, February 12, 2021 at 11:00 am ET. Conference call access information is as follows:Instant replay of the conference call will be available until Friday, February 26, 2021, at 11:00 pm ET. Instant replay access information is as follows:The live webcast of the conference call will be available on the investor section of WashREIT’s website at www.washreit.com.WashREIT owns and operates uniquely positioned real estate assets in the Washington, DC Metro area. Backed by decades of experience, expertise, and ambition, we create value by transforming...

CARNEGIE, Pennsylvania, Dec. 14, 2020 (GLOBE NEWSWIRE) — Rice Acquisition Corp. (NYSE: RICE U) (the “Company”) announced that, commencing December 14, 2020, holders of the units sold in the Company’s initial public offering may elect to separately trade the shares of Class A common stock and warrants included in the units. The shares of Class A common stock and warrants that are separated will trade on the New York Stock Exchange (the “NYSE”) under the symbols “RICE” and “RICE WS,” respectively. Those units not separated will continue to trade on the NYSE under the symbol “RICE U.” Holders of units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the units into shares of Class A common stock and warrants.This press release shall not constitute...

YAVNE, Israel, Dec. 14, 2020 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced it has further expanded its NexoBrid® global presence and entered the Middle Eastern markets with the signing of a distribution agreement granting Ghassan Aboud Group (GAG), an international conglomerate based in the United Arab Emirates (UAE), an exclusive right to market and distribute NexoBrid in UAE for the treatment of severe burns. Commercialization of NexoBrid in the UAE will commence upon securing regulatory approval, which is expected within a year.“We are truly excited to partner with GAG to bring NexoBrid to the UAE,” said Sharon Malka, Chief Executive Officer of MediWound. “This partnership...

Jobindex A/S har i dag uddelt 4000 gratis medarbejderaktier til 207 medarbejdere i Jobindex koncernen inklusive direktionen som meddelt i sidste kvartalsmeddelelse. Aktierne er købt til 1200 kr. pr. aktie svarende til en samlet værdi på 4,8 mio. kr. Medarbejdere, der har været ansat i over 25 timer om ugen i hele 2019 og 2020, får hver 20 Jobindex aktier. Aktierne er ikke båndlagte og kan således sælges med det samme. Aktierne er købt af hovedaktionæren i Jobindex A/S, Danielsen.com aps, der har solgt de 4000 Jobindex aktier til Jobindex A/S. Vedhæftet filAktiehandel medarbejderaktier 2020

 Solutions 30 has requested Euronext Paris to resume the listing of its share (FR0013379484) on the regulated market of Euronext Paris as from Tuesday 15 December 2020, at the opening of the trading.Trading in Solutions 30 shares had been suspended on Friday 11 December at the opening, at the company’s request, in the context of a campaign of destabilisation through the use of dishonest and unfair procedures.This morning the group issued a press release announcing that it had notified the AMF and lodged a criminal complaint for dissemination of false and misleading information. The company has published the necessary responses on its website to put an end to all the suspicions that this information was intended to raise. https://www.solutions30.com/transparency/In the same spirit, the Supervisory Board has appointed external experts,...

Solutions 30 a demandé à Euronext Paris de procéder à la reprise de cotation de son titre (FR0013379484) sur le marché réglementé d’Euronext Paris à compter du mardi 15 décembre 2020, à l’ouverture de la séance.La négociation des actions de Solutions 30 avait été suspendue le vendredi 11 décembre dès l’ouverture, à la demande de la société, dans le contexte d’une campagne de déstabilisation via l’utilisation de procédés malhonnêtes et déloyaux.Le groupe a publié ce matin un communiqué de presse annonçant avoir alerté l’AMF et porté plainte au pénal pour diffusion d’informations fausses et trompeuses. La société a publié sur son site les réponses nécessaires afin de mettre un terme à toutes les suspicions que ces informations avaient vocation à faire naitre : https://www.solutions30.com/transparency/Dans le même esprit, le Conseil de surveillance...

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) — BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for the purchase and sale of 1,888,889 shares of its common stock at a purchase price of $4.75 per share in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about December 16, 2020, subject to the satisfaction of customary closing conditions.A.G.P./Alliance Global Partners is acting as sole placement agent for the offering.  This offering is being made pursuant to an effective shelf registration statement on Form S-3 (File No. 333- 249426) previously filed with the U.S. Securities and Exchange Commission (the “SEC”). A prospectus supplement describing the terms of the proposed...